Dainippon Sumitomo makes good on US oncology marketing plans
This article was originally published in Scrip
Executive Summary
In a new mid-term business plan released earlier this year, Dainippon Sumitomo Pharma (DSP) said it was aiming to build up its independent US sales and marketing capability in the oncology field, using the 2012 acquisition of Boston Biomedical as a foundation.